{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:28:48Z","timestamp":1795026528534,"version":"4.10.2"},"reference-count":113,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,5,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and organ ischemia linked to disseminated microvascular platelet rich-thrombi. TTP is specifically related to a severe deficiency in ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13), the specific von Willebrand factor-cleaving protease. ADAMTS13 deficiency is most frequently acquired via ADAMTS13 autoantibodies, but rarely, it is inherited via mutations of the ADAMTS13 gene. The first acute episode of TTP usually occurs during adulthood, with a predominant anti-ADAMTS13 autoimmune etiology. In rare cases, however, TTP begins as soon as childhood, with frequent inherited forms. TTP is \u223c2-fold more frequent in women, and its outcome is characterized by a relapsing tendency. Rapid recognition of TTP is crucial to initiate appropriate treatment. The first-line therapy for acute TTP is based on daily therapeutic plasma exchange supplying deficient ADAMTS13, with or without steroids. Additional immune modulators targeting ADAMTS13 autoantibodies are mainly based on steroids and the humanized anti-CD20 monoclonal antibody rituximab. In refractory or unresponsive TTP, more intensive therapies including twice-daily plasma exchange; pulses of cyclophosphamide, vincristine, or cyclosporine A; or salvage splenectomy are considered. New drugs including N-acetylcysteine, bortezomib, recombinant ADAMTS13, and caplacizumab show promise in the management of TTP. Also, long-term follow-up of patients with TTP is crucial to identify the occurrence of other autoimmune diseases, to control relapses, and to evaluate psychophysical sequelae. Further development of both patients\u2019 registries worldwide and innovative drugs is still needed to improve TTP management.<\/jats:p>","DOI":"10.1182\/blood-2016-10-709857","type":"journal-article","created":{"date-parts":[[2017,4,17]],"date-time":"2017-04-17T21:00:22Z","timestamp":1492462822000},"page":"2836-2846","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":654,"title":["Thrombotic thrombocytopenic purpura"],"prefix":"10.1182","volume":"129","author":[{"given":"B\u00e9rang\u00e8re S.","family":"Joly","sequence":"first","affiliation":[{"name":"Service d\u2019H\u00e9matologie Biologique, H\u00f4pital Lariboisi\u00e8re, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France;"},{"name":"EA3518, Institut Universitaire d\u2019H\u00e9matologie Saint Louis, Universit\u00e9 Paris Diderot, Paris, France;"},{"name":"Centre National de R\u00e9f\u00e9rence des MicroAngiopathies Thrombotiques and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Coppo","sequence":"additional","affiliation":[{"name":"Centre National de R\u00e9f\u00e9rence des MicroAngiopathies Thrombotiques and"},{"name":"Service d\u2019H\u00e9matologie, H\u00f4pital Saint Antoine, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France; and"},{"name":"Universit\u00e9 Pierre et Marie Curie, Universit\u00e9 Paris 6, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Veyradier","sequence":"additional","affiliation":[{"name":"Service d\u2019H\u00e9matologie Biologique, H\u00f4pital Lariboisi\u00e8re, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France;"},{"name":"EA3518, Institut Universitaire d\u2019H\u00e9matologie Saint Louis, Universit\u00e9 Paris Diderot, Paris, France;"},{"name":"Centre National de R\u00e9f\u00e9rence des MicroAngiopathies Thrombotiques and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111903383742800_B1","first-page":"21","article-title":"Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease","volume-title":"Proc N Pathol Soc","author":"Moschcowitz","year":"1924"},{"issue":"6855","key":"2019111903383742800_B2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/35097008","article-title":"Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura","volume":"413","author":"Levy","year":"2001","journal-title":"Nature"},{"issue":"5","key":"2019111903383742800_B3","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1365-2141.2008.07276.x","article-title":"Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features","volume":"142","author":"Scully","year":"2008","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111903383742800_B4","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1365-2141.2010.08385.x","article-title":"Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura","volume":"151","author":"Lotta","year":"2010","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111903383742800_B5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2169\/internalmedicine.49.2706","article-title":"Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998-2008","volume":"49","author":"Fujimura","year":"2010","journal-title":"Intern Med"},{"issue":"8","key":"2019111903383742800_B6","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"Kremer Hovinga","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2019111903383742800_B7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s12185-011-0771-5","article-title":"Clinical features of severe acquired ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: the Korean TTP registry experience","volume":"93","author":"Jang","year":"2011","journal-title":"Int J Hematol"},{"issue":"12","key":"2019111903383742800_B8","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1182\/blood-2013-04-496752","article-title":"Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura","volume":"122","author":"Deford","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2019111903383742800_B9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/imj.12935","article-title":"Diagnosis and management of thrombotic thrombocytopenic purpura (TTP) in Australia: findings from the first 5 years of the Australian TTP\/thrombotic microangiopathy registry","volume":"46","author":"Blombery","year":"2016","journal-title":"Intern Med J"},{"issue":"5","key":"2019111903383742800_B10","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/S2352-3026(16)30018-7","article-title":"Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy","volume":"3","author":"Mariotte","year":"2016","journal-title":"Lancet Haematol"},{"key":"2019111903383742800_B11","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/asheducation.V2012.1.604.3798564","article-title":"Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes","volume":"2012","author":"George","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"10","key":"2019111903383742800_B12","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/pbc.24612","article-title":"Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features","volume":"60","author":"Reese","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"2019111903383742800_B13","doi-asserted-by":"crossref","first-page":"e537","DOI":"10.1016\/S2352-3026(16)30125-9","article-title":"Child- and adolescent-onset acquired thrombotic thrombocytopenic purpura with severely deficient ADAMTS13: a cohort study of 45 cases from the French Thrombotic Microangiopathies Registry","volume":"3","author":"Joly","year":"2016","journal-title":"Lancet Haematol"},{"key":"2019111903383742800_B14","first-page":"631","article-title":"What\u2019s new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura","volume-title":"Hematology Am Soc Hematol Educ Program","author":"Sadler","year":"2015"},{"issue":"23","key":"2019111903383742800_B15","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJM198212023072306","article-title":"Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura","volume":"307","author":"Moake","year":"1982","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111903383742800_B16","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0049-3848(85)90180-X","article-title":"Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen","volume":"38","author":"Asada","year":"1985","journal-title":"Thromb Res"},{"issue":"6","key":"2019111903383742800_B17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111903383742800_B18","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1182\/blood.V87.10.4223.bloodjournal87104223","article-title":"Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis","volume":"87","author":"Furlan","year":"1996","journal-title":"Blood"},{"issue":"22","key":"2019111903383742800_B19","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","article-title":"von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome","volume":"339","author":"Furlan","year":"1998","journal-title":"N Engl J Med"},{"issue":"22","key":"2019111903383742800_B20","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura","volume":"339","author":"Tsai","year":"1998","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111903383742800_B21","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/oxfordjournals.jbchem.a003009","article-title":"A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease?","volume":"130","author":"Soejima","year":"2001","journal-title":"J Biochem"},{"issue":"6","key":"2019111903383742800_B22","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood.V98.6.1765","article-title":"Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases","volume":"98","author":"Veyradier","year":"2001","journal-title":"Blood"},{"issue":"2","key":"2019111903383742800_B23","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1182\/blood-2002-02-0344","article-title":"Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura","volume":"100","author":"Bianchi","year":"2002","journal-title":"Blood"},{"issue":"11","key":"2019111903383742800_B24","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/blood-2003-11-4035","article-title":"Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura","volume":"103","author":"Zheng","year":"2004","journal-title":"Blood"},{"issue":"6","key":"2019111903383742800_B25","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.blre.2014.07.004","article-title":"Acquired TTP: ADAMTS13 meets the immune system","volume":"28","author":"Verbij","year":"2014","journal-title":"Blood Rev"},{"issue":"12","key":"2019111903383742800_B26","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1182\/blood-2003-12-4165","article-title":"Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura","volume":"103","author":"Klaus","year":"2004","journal-title":"Blood"},{"issue":"7","key":"2019111903383742800_B27","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1182\/blood-2006-02-006064","article-title":"Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity","volume":"109","author":"Ferrari","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2019111903383742800_B28","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/jth.12494","article-title":"Measurement and prevalence of circulating ADAMTS13-specific immune complexes in autoimmune thrombotic thrombocytopenic purpura","volume":"12","author":"Lotta","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2019111903383742800_B29","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1160\/TH08-01-0006","article-title":"Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis","volume":"99","author":"Uemura","year":"2008","journal-title":"Thromb Haemost"},{"issue":"2","key":"2019111903383742800_B30","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood-2004-06-2096","article-title":"Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin","volume":"105","author":"Studt","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2019111903383742800_B31","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1182\/blood-2005-03-1087","article-title":"Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure","volume":"107","author":"Ono","year":"2006","journal-title":"Blood"},{"issue":"6","key":"2019111903383742800_B32","doi-asserted-by":"crossref","first-page":"R273","DOI":"10.1186\/cc13115","article-title":"The prognostic value of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13) deficiency in septic shock patients involves interleukin-6 and is not dependent on disseminated intravascular coagulation","volume":"17","author":"Peigne","year":"2013","journal-title":"Crit Care"},{"issue":"1","key":"2019111903383742800_B33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/humu.21143","article-title":"ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura","volume":"31","author":"Lotta","year":"2010","journal-title":"Hum Mutat"},{"issue":"1","key":"2019111903383742800_B34","first-page":"e108","article-title":"Current status in diagnosis and treatment of hereditary thrombotic thrombocytopenic purpura","volume":"3","author":"Hanby","year":"2014","journal-title":"Hereditary Genet"},{"issue":"2","key":"2019111903383742800_B35","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1538-7836.2008.02846.x","article-title":"Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura","volume":"6","author":"Camilleri","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"24","key":"2019111903383742800_B36","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.1182\/blood-2012-02-408914","article-title":"Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura","volume":"119","author":"Moatti-Cohen","year":"2012","journal-title":"Blood"},{"issue":"10","key":"2019111903383742800_B37","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1172\/JCI26007","article-title":"Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice","volume":"115","author":"Motto","year":"2005","journal-title":"J Clin Invest"},{"issue":"Suppl 1","key":"2019111903383742800_B38","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/jth.12255","article-title":"Animal models for thrombotic thrombocytopenic purpura","volume":"11","author":"Vanhoorelbeke","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"17","key":"2019111903383742800_B39","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1182\/blood-2016-06-724161","article-title":"Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura","volume":"128","author":"Page","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2019111903383742800_B40","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1111\/j.1537-2995.2011.03125.x","article-title":"Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency","volume":"51","author":"Terrell","year":"2011","journal-title":"Transfusion"},{"issue":"7","key":"2019111903383742800_B41","doi-asserted-by":"crossref","first-page":"e0156679","DOI":"10.1371\/journal.pone.0156679","article-title":"Thrombotic thrombocytopenic purpura in black people: impact of ethnicity on survival and genetic risk factors","volume":"11","author":"Martino","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"2019111903383742800_B42","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1538-7836.2010.03772.x","article-title":"HLA-DRB1*11: a strong risk factor for acquired severe ADAMTS13 deficiency-related idiopathic thrombotic thrombocytopenic purpura in Caucasians","volume":"8","author":"Coppo","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2019111903383742800_B43","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1182\/blood.V98.9.2730","article-title":"Changes in health and disease of the metalloprotease that cleaves von Willebrand factor","volume":"98","author":"Mannucci","year":"2001","journal-title":"Blood"},{"issue":"1","key":"2019111903383742800_B44","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1053\/j.seminhematol.2003.10.001","article-title":"The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS","volume":"41","author":"George","year":"2004","journal-title":"Semin Hematol"},{"issue":"2","key":"2019111903383742800_B45","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/jth.12790","article-title":"Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura","volume":"13","author":"Benhamou","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2019111903383742800_B46","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/jth.12826","article-title":"Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity","volume":"13","author":"Zafrani","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"17","key":"2019111903383742800_B47","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111903383742800_B48","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1161\/ATVBAHA.111.223610","article-title":"Von Willebrand factor and ADAMTS13: a candidate couple for preeclampsia pathophysiology","volume":"31","author":"Stepanian","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"2019111903383742800_B49","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1111\/j.1538-7836.2005.01350.x","article-title":"Thrombotic thrombocytopenic purpura and its diagnosis","volume":"3","author":"Veyradier","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2019111903383742800_B50","doi-asserted-by":"crossref","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"issue":"4","key":"2019111903383742800_B51","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/vox.12050","article-title":"Performance of a clinical prediction score for thrombotic thrombocytopenic purpura in an independent cohort","volume":"105","author":"Bentley","year":"2013","journal-title":"Vox Sang"},{"issue":"5","key":"2019111903383742800_B52","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1055\/s-0037-1614779","article-title":"Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF","volume":"82","author":"Obert","year":"1999","journal-title":"Thromb Haemost"},{"issue":"5","key":"2019111903383742800_B53","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1055\/s-0037-1614780","article-title":"Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP)","volume":"82","author":"Gerritsen","year":"1999","journal-title":"Thromb Haemost"},{"issue":"1","key":"2019111903383742800_B54","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2141.2005.05420.x","article-title":"FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay","volume":"129","author":"Kokame","year":"2005","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111903383742800_B55","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1160\/TH13-05-0393","article-title":"Evaluation of a commercial assay for ADAMTS13 activity measurement","volume":"110","author":"Thouzeau","year":"2013","journal-title":"Thromb Haemost"},{"issue":"5","key":"2019111903383742800_B56","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.thromres.2014.09.006","article-title":"Evaluation of a chromogenic commercial assay using VWF-73 peptide for ADAMTS13 activity measurement","volume":"134","author":"Joly","year":"2014","journal-title":"Thromb Res"},{"issue":"6","key":"2019111903383742800_B57","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/jth.12881","article-title":"Establishment of the WHO 1st International Standard ADAMTS13, plasma (12\/252): communication from the SSC of the ISTH","volume":"13","author":"Hubbard","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2019111903383742800_B58","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/j.1538-7836.2007.02438.x","article-title":"Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies","volume":"5","author":"Meyer","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2019111903383742800_B59","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1600-0609.2012.01767.x","article-title":"Long-term management of acquired thrombotic thrombocytopenic purpura using serial plasma ADAMTS13 measurements","volume":"88","author":"Knovich","year":"2012","journal-title":"Eur J Haematol"},{"issue":"2","key":"2019111903383742800_B60","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1160\/TH13-08-0688","article-title":"FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients","volume":"112","author":"Mancini","year":"2014","journal-title":"Thromb Haemost"},{"issue":"2","key":"2019111903383742800_B61","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/trf.13359","article-title":"Effect of ADAMTS13 activity turnaround time on plasma utilization for suspected thrombotic thrombocytopenic purpura","volume":"56","author":"Connell","year":"2016","journal-title":"Transfusion"},{"issue":"3","key":"2019111903383742800_B62","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1160\/TH12-08-0565","article-title":"Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies","volume":"109","author":"Mackie","year":"2013","journal-title":"Thromb Haemost"},{"key":"2019111903383742800_B63","first-page":"637","article-title":"Treatment of thrombotic thrombocytopenic purpura beyond therapeutic plasma exchange","volume-title":"Hematology Am Soc Hematol Educ Program","author":"Coppo","year":"2015"},{"issue":"2","key":"2019111903383742800_B64","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood-2014-02-553131","article-title":"Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes","volume":"124","author":"Scully","year":"2014","journal-title":"Blood"},{"issue":"42","key":"2019111903383742800_B65","doi-asserted-by":"crossref","first-page":"e1598","DOI":"10.1097\/MD.0000000000001598","article-title":"Risk factors for autoimmune diseases development after thrombotic thrombocytopenic purpura","volume":"94","author":"Roriz","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"2019111903383742800_B66","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2141.2011.08636.x","article-title":"Human immunodeficiency virus associated thrombotic thrombocytopenic purpura--favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy","volume":"153","author":"Hart","year":"2011","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111903383742800_B67","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1200\/JOP.2016.012096","article-title":"Microangiopathic hemolytic anemia and thrombocytopenia in patients with cancer","volume":"12","author":"Morton","year":"2016","journal-title":"J Oncol Pract"},{"issue":"4","key":"2019111903383742800_B68","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1182\/blood-2003-06-1796","article-title":"Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome","volume":"103","author":"Matsumoto","year":"2004","journal-title":"Blood"},{"issue":"5","key":"2019111903383742800_B69","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1182\/blood-2002-08-2399","article-title":"von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP","volume":"101","author":"Schneppenheim","year":"2003","journal-title":"Blood"},{"issue":"1","key":"2019111903383742800_B70","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/jth.13186","article-title":"High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: from clinical observation to evidence","volume":"14","author":"von Krogh","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019111903383742800_B71","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5482\/HAMO-13-04-0026","article-title":"Hereditary thrombotic thrombocytopenic purpura and the hereditary TTP registry","volume":"33","author":"Mansouri Taleghani","year":"2013","journal-title":"Hamostaseologie"},{"issue":"18","key":"2019111903383742800_B72","doi-asserted-by":"crossref","first-page":"11902","DOI":"10.1073\/pnas.172277399","article-title":"Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity","volume":"99","author":"Kokame","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2019111903383742800_B73","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/blood-2012-01-403113","article-title":"Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura","volume":"120","author":"Lotta","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111903383742800_B74","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2003-01-0193","article-title":"ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients","volume":"102","author":"Vesely","year":"2003","journal-title":"Blood"},{"issue":"4","key":"2019111903383742800_B75","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1538-7836.2009.03285.x","article-title":"Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS 13","volume":"7","author":"Hughes","year":"2009","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2019111903383742800_B76","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3324\/haematol.2011.049676","article-title":"Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience","volume":"97","author":"Benhamou","year":"2012","journal-title":"Haematologica"},{"issue":"20","key":"2019111903383742800_B77","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1182\/blood-2010-07-271445","article-title":"How I treat patients with thrombotic thrombocytopenic purpura: 2010","volume":"116","author":"George","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111903383742800_B78","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1537-2995.2008.01938.x","article-title":"Long-term deficits in health-related quality of life after recovery from thrombotic thrombocytopenic purpura","volume":"49","author":"Lewis","year":"2009","journal-title":"Transfusion"},{"issue":"2","key":"2019111903383742800_B79","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood-2014-01-550244","article-title":"Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura","volume":"124","author":"Hie","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111903383742800_B80","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/jca.21302","article-title":"Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research","volume":"29","author":"Sarode","year":"2014","journal-title":"J Clin Apher"},{"issue":"3","key":"2019111903383742800_B81","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"Scully","year":"2012","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111903383742800_B82","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CCM.0b013e31822e9d66","article-title":"Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange","volume":"40","author":"Froissart","year":"2012","journal-title":"Crit Care Med"},{"issue":"10","key":"2019111903383742800_B83","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1111\/trf.13229","article-title":"Type of plasma preparation used for plasma exchange and clinical outcome of adult patients with acquired idiopathic thrombotic thrombocytopenic purpura: a French retrospective multicenter cohort study","volume":"55","author":"Toussaint-Hacquard","year":"2015","journal-title":"Transfusion"},{"issue":"2","key":"2019111903383742800_B84","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1046\/j.1365-2141.1996.d01-1800.x","article-title":"Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura","volume":"94","author":"Rock","year":"1996","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111903383742800_B85","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jca.1003","article-title":"Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP)","volume":"16","author":"Zeigler","year":"2001","journal-title":"J Clin Apher"},{"issue":"6","key":"2019111903383742800_B86","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00277-009-0877-5","article-title":"High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study","volume":"89","author":"Balduini","year":"2010","journal-title":"Ann Hematol"},{"issue":"6","key":"2019111903383742800_B87","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1056\/NEJM199108083250605","article-title":"Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients","volume":"325","author":"Bell","year":"1991","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111903383742800_B88","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1600-0609.2009.01292.x","article-title":"Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature","volume":"83","author":"Elliott","year":"2009","journal-title":"Eur J Haematol"},{"issue":"7","key":"2019111903383742800_B89","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019111903383742800_B90","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/jca.20172","article-title":"Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature","volume":"23","author":"Jasti","year":"2008","journal-title":"J Clin Apher"},{"issue":"7","key":"2019111903383742800_B91","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ajh.21439","article-title":"Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature","volume":"84","author":"Ling","year":"2009","journal-title":"Am J Hematol"},{"issue":"3","key":"2019111903383742800_B92","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.transci.2010.09.018","article-title":"Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study","volume":"43","author":"de la Rubia","year":"2010","journal-title":"Transfus Apheresis Sci"},{"issue":"24","key":"2019111903383742800_B93","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1182\/blood-2016-03-703827","article-title":"Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura","volume":"127","author":"Page","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2019111903383742800_B94","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.2006.06448.x","article-title":"Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13","volume":"136","author":"Scully","year":"2007","journal-title":"Br J Haematol"},{"issue":"24","key":"2019111903383742800_B95","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1182\/blood-2016-04-710475","article-title":"Adjuvant rituximab to prevent TTP relapse","volume":"127","author":"Cuker","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2019111903383742800_B96","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1182\/blood-2014-10-559211","article-title":"The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura","volume":"125","author":"Lim","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2019111903383742800_B97","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1537-2995.2005.03146.x","article-title":"Combination vincristine and plasma exchange as initial therapy in patients with thrombotic thrombocytopenic purpura: one institution\u2019s experience and review of the literature","volume":"45","author":"Ziman","year":"2005","journal-title":"Transfusion"},{"issue":"5","key":"2019111903383742800_B98","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/ajh.21385","article-title":"Cyclosporine therapy in refractory\/relapsed patients with thrombotic thrombocytopenic purpura","volume":"84","author":"Nosari","year":"2009","journal-title":"Am J Hematol"},{"issue":"3","key":"2019111903383742800_B99","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2141.2007.06819.x","article-title":"Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity","volume":"139","author":"Cataland","year":"2007","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"2019111903383742800_B100","doi-asserted-by":"crossref","first-page":"S223","DOI":"10.1111\/jth.12934","article-title":"Acquired thrombotic thrombocytopenic purpura: new therapeutic options and their optimal use","volume":"13","author":"Cataland","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2019111903383742800_B101","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1172\/JCI41062","article-title":"N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice","volume":"121","author":"Chen","year":"2011","journal-title":"J Clin Invest"},{"issue":"1","key":"2019111903383742800_B102","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1056\/NEJMc1213206","article-title":"ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura","volume":"368","author":"Shortt","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111903383742800_B103","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/j.1538-7836.2011.04224.x","article-title":"Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies","volume":"9","author":"Plaimauer","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"25","key":"2019111903383742800_B104","doi-asserted-by":"crossref","first-page":"6128","DOI":"10.1182\/blood-2011-09-380535","article-title":"A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13","volume":"119","author":"Schiviz","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2019111903383742800_B105","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111903383742800_B106","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1182\/blood-2014-11-551580","article-title":"How I treat refractory thrombotic thrombocytopenic purpura","volume":"125","author":"Sayani","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2019111903383742800_B107","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1537-2995.2007.01530.x","article-title":"Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006","volume":"48","author":"Nguyen","year":"2008","journal-title":"Transfusion"},{"issue":"11","key":"2019111903383742800_B108","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1111\/j.1537-2995.2012.03578.x","article-title":"Splenectomy and\/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience","volume":"52","author":"Beloncle","year":"2012","journal-title":"Transfusion"},{"issue":"2","key":"2019111903383742800_B109","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1537-2995.2008.02030.x","article-title":"Complications of plasma exchange in patients treated for thrombotic thrombocytopenic purpura. IV. An additional study of 43 consecutive patients, 2005 to 2008","volume":"49","author":"Nguyen","year":"2009","journal-title":"Transfusion"},{"issue":"5","key":"2019111903383742800_B110","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF01784041","article-title":"The role of splenectomy in the treatment of relapsing thrombotic thrombocytopenic purpura","volume":"70","author":"Veltman","year":"1995","journal-title":"Ann Hematol"},{"issue":"5","key":"2019111903383742800_B111","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2141.2005.05681.x","article-title":"Splenectomy for the treatment of thrombotic thrombocytopenic purpura","volume":"130","author":"Kappers-Klunne","year":"2005","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111903383742800_B112","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1046\/j.1365-2141.2001.02808.x","article-title":"Ten years of prophylactic treatment with fresh-frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor-cleaving protease","volume":"113","author":"Barbot","year":"2001","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111903383742800_B113","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00467-008-0863-5","article-title":"Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children","volume":"24","author":"Loirat","year":"2009","journal-title":"Pediatr Nephrol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/21\/2836\/1401449\/blood709857.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/21\/2836\/1401449\/blood709857.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T12:16:57Z","timestamp":1719145017000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/21\/2836\/36273\/Thrombotic-thrombocytopenic-purpura"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,25]]},"references-count":113,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2017,5,25]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-10-709857","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,25]]}}}